Funding for this research was provided by:
Health Research Council of New Zealand (14/527)
Received: 4 July 2020
Accepted: 18 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: The study was approved by the New Zealand Health and Disability Ethics Committee (MEC/05/10/130), and each participant gave written informed consent.
: Not applicable
: ND reports grants and personal fees from AstraZeneca, grants from Amgen, and personal fees from Dyve Biosciences, Selecta, Hengrui, Horizon, Abbvie, Pfizer, Janssen, and Arthrosi, outside the submitted work. The other authors have no relevant conflicts of interest.